Bogan Sleep Consultants, LLC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$714,696	516
2024	Research	$467,518	285
2023	Research	$445,508	123
2022	Research	$188,065	11
2021	Research	$245,479	14
2020	Research	$226,754	36
2019	Research	$137,214	14

Breakdown

Who paid Research payments · program years 2019–2025

Jazz Pharmaceuticals Inc. $757,674 387 payments
Alkermes, Inc. $647,284 449 payments
LivaNova USA, Inc. $470,968 95 payments
iRhythm Technologies, Inc. $244,471 13 payments
Merck Sharp & Dohme Corporation $204,432 20 payments
Harmony Biosciences LLC $92,900 31 payments
Noctrix Health, Inc. $7,505 4 payments

Studies the money was for Research payments · program years 2019–2025

(OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation $440,426 21 payments
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 $331,437 216 payments
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (Xywav) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia Or Narcolepsy $289,219 196 payments
A Phase 4 Multicenter, Open-Label, Single-Arm Study of Safety, Tolerability, Effectiveness and Treatment Optimization in Participants Switching From Xyrem to Xywav for the Treatment of Narcolepsy $234,231 54 payments
iRhythm Sleep and Activity Dataset Study (iSLEEP - ZZZio) $204,471 12 payments
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) $151,211 83 payments
Clinical Trial to Characterize Symptoms of Excessive Daytime SleepinessFollowing Treatment Withdrawal in Participants with Narcolepsy Type 1. $129,702 5 payments
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia $128,364 103 payments
A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of Jzp-258 in the Treatment of Idiopathic Hypersomnia (Ih) With An Open-Label Safety Extension $98,446 35 payments
Jzp080-301 A Double-Blind, Placebo-Controlled, Ramdomized Withdrawal, Multicenter Study of the Efficacy and Safety of Jzp-258 in the Treatment of Idiopathic Hypersommnia (Ih) With An Open-Label Safety Extention $81,762 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.